ART 34 AMDT

1. A polymer drug conjugate comprising:

i) at least one anti-cancer agent; and

ii) a dextrin polymer, wherein said dextrin polymer is modified by succinoylation by at least 20mol% characterised in that the stability of the polymer drug conjugate is enhanced.

2. A polymer drug conjugate according to claim 1, wherein said dextrin is succinoylated to at least 30mol%.

3. A polymer drug conjugate according to Claim 2, wherein said dextrin is succinoylated from 30% to 40mol%.

4 A polymer drug conjugate according to Claim 3, wherein said dextrin is succinoylated from 32% to 36mol%.

5. A polymer drug conjugate according to Claim 4 wherein said dextrin is succinoylated to about 34mol%.

6. A polymer drug conjugate according to any of Claims 1-5 wherein the percentage of α-1-6 linkages in the dextrin is less than 10%.

7. A polymer drug conjugate according to Claim 6 wherein the percentage of α 1-6 linkages in the dextrin is less than 5%.

8. A polymer drug conjugate according to any of Claims 1-7 wherein the molecular weight of the dextrin is in the average molecular weight range 1000-200000.

9. A polymer drug conjugate according to Claim 8 wherein the molecular weight of the dextrin is in the average molecular weight range 2000-55000.

10. A polymer drug conjugate according to any of Claims 1-9 wherein the dextrin

ART 34 AMDT

contains more than 15% of polymers of DP greater than 12.

11. A polymer drug conjugate according to Claim 10 wherein the dextrin contains more than 50% of polymers of DP greater than 12.

12. A polymer drug conjugate according to any of Claims 1-13, wherein said anti cancer agent is selected from the group consisting of: cyclophosphamide; melphalan; carmusline; methotrexate, 5-fluorouracil; cytarabine; mercaptopurine; anthracyclines; daunorubicin, doxorubicin; epirubicin; vinca alkaloids; vinblastin; vincristine; dactinomycin; mitomycin C; taxol; L-asparaginase; G-CSF; cisplatin; carboplatin

13. A pharmaceutical composition comprising a polymer drug conjugate according to any of Claims 1-12.

14 A pharmaceutical composition according to Claim 13 wherein said composition comprises a diluent, carrier or excipient.

15. The use of a polymer drug conjugate according to any of Claims 1-12 for the manufacture of a medicament for the treatment of cancer.

16. A polymer drug conjugate comprising:

i) at least one biologically active agent; and

ii) a dextrin polymer, wherein said dextrin polymer is modified by succinoylation by at least 20mol% characterised in that the stability of the polymer drug conjugate is enhanced.

17. A polymer conjugate according to Claim 16 wherein said agent is an imaging agent.

18. A polymer conjugate according to Claim 17 wherein the imaging agent is tyrosinamide.

ART 34 AMDT

19. A polymer conjugate according to Claim 16 wherein said agent is a diagnostic agent;

20. A polymer conjugate according to Claim 16 wherein said agent is a targeting agent.

21. A polymer conjugate according to Claim 20 wherein the targeting agent is biotin.

22. A method of treatment of an animal subject the method including the administration to the animal a pharmaceutically effective amount of the polymer drug conjugate according to any of Claims 1-12.

23. A method of treatment according to Claim 22 wherein said animal is human.

TABLE 2

Compound	Dose mg kg^{-1} (day 0,1,2)	Days survival after treatment (mean ± SD)	T/C (%)	Toxic deaths
Control (saline)	-	4.3± 0.5	100	0/6
doxorubicin	5	4.5 ± 0.5^{ns}	103	0/6
Dextrin-Dox	5	6.2 ±0.8*	142	0/6
Dextrin -Dox	10	6.0 ±1.1**	138	0/6

N= 6 ns = not significant * p = 0.0004 ** p = 0.005